

# Breast Cancer Pathways: Neoadjuvant

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_  
Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_  
Pathology: \_\_\_\_\_ Stage: \_\_\_\_\_  
Line of Therapy: \_\_Neoadjuvant/Pre-Op \_\_Adjuvant/Post-Op ECOG Performance Status: \_\_\_\_\_ ICD-10 Code: \_\_\_\_\_  
Biomarkers/Characteristics: (Select all that apply)  
Estrogen Receptor (ER): \_\_Negative \_\_Positive OncotypeDx: \_\_Low \_\_Intermediate  
Progesterone Receptor (PR): \_\_Negative \_\_Positive \_\_High \_\_Not Done/Reported  
HER2 status by FISH/CISH: \_\_Negative \_\_Positive \_\_Equivocal Menopausal Status: \_\_Pre \_\_Peri  
or by IHC: \_\_0 \_\_1+ \_\_2+ \_\_3+ \_\_Post \_\_N/A (patient is male)

## Neoadjuvant Therapy | HER2 Negative

\_\_\_**ddAC** → **weekly T**: dose dense doxorubicin (Adriamycin) and cyclophosphamide followed by weekly paclitaxel  
\_\_\_**TC**: docetaxel (Taxotere) and cyclophosphamide

## Neoadjuvant Therapy | HER2 Positive

\_\_\_**AC** → **TH**: doxorubicin (Adriamycin) and cyclophosphamide followed by paclitaxel and trastuzumab (Herceptin)\*  
\_\_\_**TCH**: docetaxel (Taxotere), carboplatin, and trastuzumab (Herceptin)\*

## Neoadjuvant Therapy | HER2 Positive | Hormone Receptor (ER/PR) Negative

\_\_\_**TCH+P**: docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin)\*, and pertuzumab (Perjeta)

\*Administration of trastuzumab (Herceptin) is limited to 17 cycles (approximately 1 year)

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

